Need an Adderall Prescription? Good Luck Getting It Over Telehealth.

“During the early stages of the COVID pandemic, the Drug Enforcement Administration (DEA) temporarily lifted restrictions on doctors’ ability to write prescriptions for controlled drugs via telehealth. However, the agency is poised to bring telehealth under regulation again, bringing back strict limits on how and when doctors can prescribe certain drugs.

DEA officials announced the proposed regulations on Friday. The rules would render most controlled drugs ineligible for prescription via telemedicine appointment—severely restricting patients’ ability to obtain drugs without an in-person examination.”

“However, the proposal contains several carve-outs. Under the policy, Schedule III-V controlled medications can still be prescribed via telemedicine. But patients would be limited to a 30-day supply, after which the patient would be required to have an in-person visit in order to get a refill. The same exception applies to buprenorphine, a drug used to treat opioid substance abuse. Further, under the proposed rule, patients can get indefinite prescriptions for controlled substances via telehealth but only if they are referred to a telehealth physician after receiving an in-person examination by another doctor.”

“Officials justified the regulations by citing concerns over the risk of overprescription of controlled drugs. While administration officials did mention the benefits that telehealth services bring to rural Americans, there is little consideration of how these services are equally important to many who rely on controlled drugs—and the increased risk that desperate patients will turn to significantly more dangerous drugs to alleviate their symptoms.
“As a health policy lawyer w. chronic pain & ADHD, I cannot overstate how unnecessary & cruel this policy is given what visits look like in person v. Telehealth,” wrote health policy lawyer Madeline T. Morcelle on Twitter. “Or how deadly this could be for those who struggle to get to [appointments] due to disability or transport/geographic barriers.””

Telemedicine Abortion Gets Green Light From Federal Court

“Under current rules set by the U.S. Food and Drug Administration (FDA), non-surgical abortion— i.e., the kind that’s induced by pharmaceuticals, not physicians—still requires patients to visit a hospital, doctor’s office, or medical clinic to be prescribed the abortion drugs, even though a patient will go through the process at home.

“A medical or medication abortion uses two drugs to terminate a pregnancy,” explains a new report, “Prescription Denied: Accessing the Abortion Pill,” from Newsy. The first of these pills, mifepristone, “blocks a hormone to induce the abortion. The second drug, misoprostol, completes it by expelling the pregnancy. But mifepristone, which for medication abortion goes by the brand name Mifeprex, is among the most restricted drugs in the U.S. which makes it challenging to get. … the Food and Drug Administration imposes tighter restrictions on Mifeprex than on opioids such as fentanyl.”

The American College of Obstetricians and Gynecologists (ACOG), the National Women’s Health Network (NWHN), and other groups have been pushing the FDA to revise its rules so that abortion patients can see doctors via telemedical appointments and then receive their pills in the mail.

“If the laws and regulations that determine the terms of abortion access in the United States were based on science—not politics—medication abortion would be widely available in the United States without medically unnecessary restrictions on distribution,” states an open letter signed by a range of physicians and health and advocacy groups.”

“U.S. District Judge Theodore Chuang seemed to be in agreement with these advocates and doctors, writing in his decision that “in-person requirements” for abortion pills present a “substantial obstacle” to patients and are likely unconstitutional.”